UH-NIP-16

UH-NIP-16

• UNSPSC Description: UH-NIP-16 exhibits antimicrobial activity against Mycobacterium tuberculosis, with MIC50 of 1.86 and 3.05 μM, for pathogenic mycobacterial strains H37Rv and CDC1551. UH-NIP-16 synergizes with Streptomycin (HY-B1906), Isoniazid (HY-B0329), Ethambutol (HY-B0535) and Bedaquiline (HY-14881), potentiates their anti-tuberculosis activities[1].
• Target Antigen: Bacterial
• Type: Reference compound
• Related Pathways: Anti-infection
• Applications: COVID-19-immunoregulation
• Field of Research: Infection
• Assay Protocol: https://www.medchemexpress.com/uh-nip-16.html
• Solubility: 10 mM in DMSO
• Smiles: O=C(N/N=C\C1=CC2=CC(OC)=CC=C2N=C1Cl)C3=CC=NC=C3
• Molecular Weight: 340.76
• References & Citations: [1]Vadankula GR, et al., Confronting Tuberculosis: A Synthetic Quinoline-Isonicotinic Acid Hydrazide Hybrid Compound as a Potent Lead Molecule Against Mycobacterium tuberculosis. ACS Infect Dis. 2024 May 8.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported